| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10963239 | Vaccine | 2015 | 6 Pages |
Abstract
The study suggests that in adults 50-64 years of age, IIV3-HD may improve immunogenicity compared to IIV3-SD while maintaining an acceptable safety profile.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Carlos A. DiazGranados, William Saway, James Gouaux, Mira Baron, Jeffrey Baker, Martine Denis, Emilia Jordanov, Victoria Landolfi, Eddy Yau,